Research library
AngioDynamics, Inc. (ANGO): the bull case and the bear case
AngioDynamics, Inc. · NASDAQ · Equity · Stock
The synthesis
Strong Med Tech segment growth and positive free cash flow are offset by persistent operating losses and a bearish technical trend.
- Med Tech segment momentum
The high-growth Med Tech business, including Auryon and NanoKnife, grew 18.4% in fiscal 2026 and continued to drive a 6.9% total revenue increase in Q1 2027 (8-K Item 2.02, 2026-10-08).
- Positive cash flow generation
Despite operational headwinds, the company achieved a positive free cash flow margin of 0.4% and maintains a net cash position of $34.0M, providing a buffer for ongoing restructuring.
- Strategic leadership transition
The appointment of Eric Honroth as President and CEO, effective November 2026, provides a fresh strategic narrative focused on R&D and regulatory expansion (8-K Item 5.02, 2026-10-08).
- Oversold technical indicators
Technical metrics suggest a potential reversal as the Stochastic %K has reached 3.4 and the RSI is at 33.0, indicating the stock is in deep oversold territory following the recent sell-off.
- Persistent operational losses
The company reported a -9.7% operating margin and a negative ROE of -19.2%, with FY2027 EPS guidance remaining in negative territory between -$0.29 and -$0.24.
- Revenue execution risks
Q1 2027 revenue of $80.9 million lagged analyst expectations, and the company notes that capital equipment sales remain lumpy and unpredictable.
- Supply chain vulnerabilities
Per the 10-K, the company is 'dependent on single and limited source suppliers' which creates significant risk for business interruptions and margin pressure.
- Severe technical breakdown
The stock is trading significantly below its 50-day ($15.45) and 200-day ($12.50) moving averages, with the latter now acting as a formidable resistance level.
Catalysts
- CEO transition effective date Nov 2
- Q2 FY2027 earnings Jan 2027
- Manufacturing restructuring updates Ongoing
- ALPHA-PE research results Near-term
Risks
- Operating margin pressure -9.7% TTM
- Single-source suppliers Material risk
- Product liability exposure Ongoing
- Capital sales volatility Lumpy
What would change the view
A shift to a more bullish outlook would require the operating margin to trend toward breakeven alongside a sustained breakout above the 200-day moving average. Conversely, a move toward the 52-week low of $9.39 or a deceleration in Med Tech segment growth would strengthen the bearish case.
Insider activity
Open-market purchases and sales reported by company insiders on SEC Form 4, from EDGAR. Share counts and dates only.
Trailing 3 months: 0 open-market purchases by 0 insiders and 1 sale by 1 insider. Net selling (Limited — 1 insider selling).
| Insider | Role | Side | Shares | Trade date | Filing |
|---|---|---|---|---|---|
| Nighan Warren JR | Officer · SVP Quality and Regulatory | Sale | 23,370 | 2026-07-30 | Form 4 |
Sources
- FMP · ANGO daily prices and technical indicators Analyst note
- FMP · ANGO financial statements (income / balance / cash flow) SEC filing
- SEC EDGAR · ANGO full-text filing search SEC filing
- SEC · DEFA14A filed 2026-10-08 SEC filing · DEFA14A · 2026-10-08
- SEC · DEF 14A filed 2026-10-08 SEC filing · DEF 14A · 2026-10-08
- SEC · 8-K filed 2026-10-08 (Items 2.02, 7.01, 9.01) SEC filing · 8-K · 2026-10-08
- SEC · 8-K filed 2026-10-08 (Items 1.01, 5.02, 9.01) SEC filing · 8-K · 2026-10-08
- SEC · 10-K/A filed 2026-09-29 SEC filing · 10-K/A · 2026-09-29
- SEC · 10-K/A filed 2026-09-29 SEC filing · 10-K/A · 2026-09-29
- SEC · 4 filed 2026-07-31 SEC filing · 4 · 2026-07-31
- SEC · 144 filed 2026-07-30 SEC filing · 144 · 2026-07-30
- SEC · 4 filed 2026-07-24 SEC filing · 4 · 2026-07-24
- SEC · 4 filed 2026-07-24 SEC filing · 4 · 2026-07-24
- SEC · 4 filed 2026-07-24 SEC filing · 4 · 2026-07-24
- SEC · 4 filed 2026-07-24 SEC filing · 4 · 2026-07-24
- SEC · 4 filed 2026-07-24 SEC filing · 4 · 2026-07-24
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-22 SEC filing · 4 · 2026-07-22
- SEC · 4 filed 2026-07-21 SEC filing · 4 · 2026-07-21
- SEC · 4 filed 2026-07-21 SEC filing · 4 · 2026-07-21
- SEC · 4 filed 2026-07-21 SEC filing · 4 · 2026-07-21
- SEC · 4 filed 2026-07-21 SEC filing · 4 · 2026-07-21
- SEC · 4 filed 2026-07-21 SEC filing · 4 · 2026-07-21
- SEC · 4 filed 2026-07-21 SEC filing · 4 · 2026-07-21
- SEC · 10-K filed 2026-07-14 SEC filing · 10-K · 2026-07-14
- SEC · 8-K filed 2026-07-14 (Items 2.02, 7.01, 9.01) SEC filing · 8-K · 2026-07-14
- MarketBeat · AngioDynamics Q1 Earnings Call Highlights News
- Zacks Investment Research · AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates News
- Defense World · AngioDynamics (NASDAQ:ANGO) Announces FY 2027 Earnings Guidance News
- Business Wire · AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and P News
- Business Wire · AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer News
- Business Wire · AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-Wo News
Read the full analysis in the app
This page publishes the written thesis. The app adds the sections not published here:
- Fundamentals
- Technicals
- News with bull, bear, and neutral tags
- 7-day news sentiment and earnings-call tone
- Forward analyst estimates
- Earnings-call summary
